en · de · es · fr · pt
cardarine-notes.peptides6579.com › Guide › Background And Research Context — What the Evidence Shows

Background And Research Context — What the Evidence Shows

By Editorial Desk · published 2026-07-22 · last reviewed 2026-08-01 · Guide

The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.

Background and Research Context

In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.

Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.

Background and Regulatory Status

Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.

Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.

Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.

Cardarine at a glance

PropertyValueNotes
CAS Registry Number317318-70-0Unique identifier for the compound.
Chemical classPPARδ agonistSynthetic ligand for peroxisome proliferator-activated receptor delta.
AppearanceWhite to off-white solidTypical form of research-grade material.
SolubilitySoluble in DMSO and ethanolPoorly soluble in water.
Typical storage-20°CRecommended for long-term storage of stock solutions.

Mechanism and Laboratory Detection

Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.

Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.

GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.

Related pages on this site

Mechanism and Detection

Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.

GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.

Mechanism and Detection Methods

Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.

Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.

Supporting material

Members of the National Union of Journalists working for the BBC regional service in England vote to take strike action over planned cuts to BBC Local Radio. A 24-hour strike is scheduled for 15 March to coincide with Budget Day.

== Novel chiral selectors and CSPs == During the last couple of years there has been developments of CSPs based on novel chiral selectors viz. chitosan derivatives, cylofructan derivatives and chiral porous materials for HPLC chiral separation.

== B == bacillary band – bacteria – bacteriochlorin – bark – Barr body – basal body – basal metabolic rate – base – base pair – basement membrane – basidiomycetes – basidium – B cell – benthic zone – beta sheet – binary fission – binding site – bioassay – biodiversity – bioenergetics – biogeochemical cycle – biological magnification – bioluminescence – biome – biopolymer – biosphere – blood – blood–brain barrier – blotting – bond energy – book lung – botany – bottleneck effect – Bowman capsule – brain stem – bronchiole – Brønsted acid – Brønsted base – Brownian movement – bryophyte – bubonic plague – budding – bulk flow

== Precursors == The earliest use of chromatography is sometimes attributed to German chemist Friedlieb Ferdinand Runge, who in 1855 described the use of paper to analyze dyes. Runge dropped spots of different inorganic chemicals onto circles of filter paper already impregnated with another chemical, and reactions between the different chemicals created unique color patterns. According to historical analysis of L. S. Ettre, however, Runge's work had "nothing to do with chromatography" (and instead should be considered a precursor of chemical spot tests such as the Schiff test). In the 1860s, Christian Friedrich Schönbein and his student Friedrich Goppelsroeder published the first attempts to study the different rates at which different substances move through filter paper. Schönbein, who thought capillary action (rather than adsorption) was responsible for the movement, called the technique capillary analysis, and Goppelsroeder spent much of his career using capillary analysis to test the movement rates of a wide variety of substances. Unlike modern paper chromatography, capillary analysis used reservoirs of the substance being analyzed, creating overlapping zones of the solution components rather than separate points or bands. Work on capillary analysis continued, but without much technical development, well into the 20th century. The first significant advances over Goppelsroeder's methods came with the work of Raphael E.

Drugs administered through topical application can act locally or systemically. However, the drug molecules must first be retained in and penetrate the surface layer of the skin. Absorption of the drug through the skin surface is a passive process of diffusion. Skin penetration of the drug can take place by passive diffusion directly through the epidermis (via transcellular or intercellular routes), or absorption through shunt routes (diffusion through hair follicles and sweat glands). Initially, drug absorption may take place via the transfolliar route. After the drug reaches a steady state, transepidermal absorption may replace transfolliar absorption as the main pathway for absorption. Drug absorption through the skin varies depending on the concentration gradient between the surface of the skin and the body, with a higher rate of absorption resulting from a greater concentration gradient. The rate of drug absorption can be maintained at a constant level by ensuring that the drug concentration at the surface of the skin remains consistently and substantially greater than that in the body. The rate of penetration of the drug across the skin barrier depends on the physiological factors, physicochemical properties of the drug, and gel characteristics. Physiological factors include skin properties, size of application area, frequency and force of application. Physicochemical properties of the drug include drug solubility, affinity for the skin, and metabolism. Gel characteristics include stability, thermodynamic activity, and occlusive properties.

Sources: en.wikipedia.org

Notes from published material

Necrophagous beetles have evolved many diet-related adaptations. For example, Nicrophorus species have specialized olfactory sensors on their antennae to help them detect carrion. These sensors are sensitive to dimethyl sulphide and other sulfur-containing compounds emitted by bodies after death. Also, Nicrophorus, Necrodes and other necrophagous silphine beetle species are flight-capable, making it easier for them to reach carrion. Nicrophorus and Dermestes species have many defenses against dietary pathogens and toxins too. These include physical traits such as protective gut linings, antibacterial lectins and lysozymes, mutualistic relationships with microbiota bacteria, and behavioral traits such as preferentially selecting fresh carcasses and smearing carcasses with antibacterial and toxin-degrading exudates. Given the often-limited availability of carrion, the ability of these beetles to share this resource with other beetles and defend it against flies and ants is also an advantage. Regarding food preferences and the logistics of carrion use, N. vespilloides and other burying beetles favor small carcasses (e.g. rodents and small birds) as these are easier to transport, clean and conceal from competitors. Diving beetles, scarab beetles and water scavenger beetles have all been observed feeding on amphibian carrion (e.g. granular toads and tree frogs). The scarab beetle Scybalocanthon nigriceps uses its front legs and clypeus to shape frog carrion into pellets for eventual consumption.

2020 Indian agriculture acts Atal Bhujal Yojana E-NAM for online agrimarketing Gramin Bhandaran Yojana for local storage Micro Irrigation Fund (MIF) National Mission For Sustainable Agriculture (NMSA) National Scheme on Fisheries Training and Extension National Scheme on Welfare of Fishermen Pradhan Mantri Kisan Samman Nidhi (PMKSN) for minimum support scheme Pradhan Mantri Krishi Sinchai Yojana (PMKSY) for irrigation Paramparagat Krishi Vikas Yojana (PKVY) for organic farming Pradhan Mantri Fasal Bima Yojana (PMFBY) for crop insurance In July 2025, the Union Cabinet raised the outlay for the Pradhan Mantri Kisan Sampada Yojana (PMKSY) to ₹6,520 crore, including ₹1,920 crore additional funding for the 15th Finance Commission cycle. The approval supports 50 food irradiation units and 100 NABL-accredited food testing labs under the scheme’s cold chain and food safety components.

=== Legacy and claims of responsibility === Multiple claims of responsibility have continued to be put forward years after the recovery of the pumpkin. In 1999, editor-in-chief of the school paper Farhad Manjoo received an anonymous tip which potentially explained how the prank was carried out, involving a climb up the spire of the tower and the use of duct tape. The May 2000 Graduation issue of the Cornell Daily Sun stated that the prank was carried out by one Cornell student ringleader and two other Ithacan accomplices. In the Cornell Chimes Newsletter, it was stated that a student from the University of Montana, "Rob", confessed to former Head Chimesmaster Courtney Kimball that they had placed the pumpkin; Atlas Obscura deemed this inauthentic, though Cornell historian Ryan Earle stated that this was "the best source for how it happened." One rumor also claimed that the prankster's identity was passed down through each university archivist. In 2017, 20 years following the placement of the first pumpkin atop the tower, Manjoo, then reporter at The New York Times, called the event "the greatest prank in Cornell history" and that there was "no downside" in the pranksters coming forward as "all of that has passed now. Now they're just legends." Evan Fay Earle, the university archivist in 2017, stated that the pumpkin "continue[d] to generate interest at Cornell and [in] the community". The website about the pumpkin was partially brought back online for the anniversary.

Insulin coma therapy was a labour-intensive treatment that required trained staff and a special unit. Patients, who were almost invariably diagnosed with schizophrenia, were selected on the basis of having a good prognosis and the physical strength to withstand an arduous treatment. There were no standard guidelines for treatment. Different hospitals and psychiatrists developed their own protocols. Typically, injections were administered six days a week for about two months. The daily insulin dose was gradually increased to 100–150 units (1 unit = 34.7 μg) until comas were produced, at which point the dose would be levelled out. Occasionally, doses of up to 450 units were used. After about 50 or 60 comas, or earlier if the psychiatrist thought that maximum benefit had been achieved, the dose of insulin was rapidly reduced before treatment was stopped. Courses of up to 2 years have been documented. After the insulin injection patients would experience various symptoms of decreased blood glucose: flushing, pallor, perspiration, salivation, drowsiness or restlessness. Sopor and coma—if the dose was high enough—would follow. Each coma would last for up to an hour and be terminated by intravenous glucose or via naso-gastric tube. Seizures occurred before or during the coma. Many would be tossing, rolling, moaning, twitching, spasming or thrashing around.

Sources: en.wikipedia.org

Background from the literature

== Background == During the Trump administration's second term, the US intensified its focus on drug cartels, characterizing the smugglers as terrorists. In August 2025, the US deployed warships and personnel to the Caribbean, citing the need to combat drug cartels. PBS News reported that Trump was using the military to counter cartels he blamed for trafficking fentanyl and other illicit drugs into the US and for fueling violence in American cities.

space. The boundaries of the shaded regions in the figure are the boundaries of stability in the two directions (also known as boundaries of bands). The domain of overlap of the two regions is the trapping domain. For calculation of these boundaries and similar diagrams as above see Müller-Kirsten.

=== Decommunization === Stephen Holmes of the University of Chicago argued in 1996 that decommunization, after a brief active period, quickly ended in near-universal failure. After the introduction of lustration, demand for scapegoats has become relatively low, and former communists have been elected for high governmental and other administrative positions. Holmes notes that the only real exception was former East Germany, where thousands of former Stasi informers have been fired from public positions. Holmes suggests the following reasons for the failure of decommunization:

Solution effects As ice crystals grow in freezing water, solutes are excluded, causing them to become concentrated in the remaining liquid water. High concentrations of some solutes can be very damaging. Extracellular ice formation When tissues are cooled slowly, water migrates out of cells and ice forms in the extracellular space. Too much extracellular ice can cause mechanical damage to the cell membrane due to crushing. Dehydration Migration of water, causing extracellular ice formation, can also cause cellular dehydration. The associated stresses on the cell can cause damage directly. Intracellular ice formation While some organisms and tissues can tolerate some extracellular ice, any appreciable intracellular ice is almost always fatal to cells.

Tartaric acid, an acid that forms diastereomeric salts with chiral amines Antimony potassium tartrate, an anion, that forms diastereomeric salts with chiral cations. Mandelic acid, an acid that forms diastereomeric salts with chiral amines. Camphorsulfonic acid, an acid that forms diastereomeric salts with chiral amines. Also 3-bromocamphor-8-sulfonic acid 1-Phenylethylamine, a base that forms diastereomeric salts with chiral acids. Many related chiral amines have been demonstrated.

Sources: en.wikipedia.org

Frequently asked questions

What is cardarine?

Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.

Is cardarine a steroid?

No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.

What did animal studies find?

Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.

Is cardarine approved for human use?

No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.

Network